| Abstract | ||||||||||||||
Nature
has always been a highly productive tool in the development of
anticancer therapies. Renewed interest in the potential of this tool
has recently been sparked by the realization that the marine ecosystem
can be used for the discovery and development of new compounds with
clinical potential in advanced resistant tumors. These compounds can be
incorporated into combination approaches in a chronic therapy scenario.
Our marine anticancer program is using the sea to develop new agents
with activity in resistant solid tumors and to identify new cellular
targets for therapeutic intervention. This review describes the
integration of different pharmacogenomic tools in the development of
Yondelis™, Aplidin® and Kahalalide F, three marine-derived
compounds currently in Phase II or III development. Our results are
reinforcing the targeted selectivity of these agents and opening the
gates for customized therapies in cancer patients in the near future.
PharmaMar R & D, Colmenar Viejo, Madrid, Spain Journal of Translational Medicine 2006, 4:3 doi:10.1186/1479-5876-4-3 The electronic version of this article is the complete one and can be found online at: http://www.translational-medicine.com/content/4/1/3
© 2006 Jimeno et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |